Abstract
Classification of plasma lipoproteins on the basis of apolipoprotein (apo) composition recognizes two lipoprotein (Lp) classes, one of which is characterized by apoA-I and the other by apoB as major protein constituents. The former lipoprotein class consists of three major subclasses referred to (according to their apolipoprotein constituents) as Lp-A-I, Lp-A-I:A-II, and Lp-A-II, and the latter one of five subclasses called Lp-B, Lp-B:E, Lp-B:C, Lp-B:C:E, and Lp-A-II:B:C:D:E. As polydisperse systems of particles, the apoA-I-containing lipoproteins overlap in high-density segments and apoB-containing lipoproteins in low-density segments of the density gradient. Each subclass is characterized by a specific chemical composition and metabolic property. Normolipidemia and dyslipoproteinemias are characterized by quantitative rather than qualitative differences in the levels of apoA- and apoB-containing subclasses. Furthermore, apoA-containing subclasses seem to differ with respect to their relative antiatherogenic capacities, and apoB-containing subclasses regarding their relative atherogenic potentials. Whereas Lp-A-I may have a greater antiatherogenic capacity than other apoA-containing subclasses, the cholesterol-enriched Lp-B:C appears to be the most atherogenic subclass among apoB-containing lipoprotein families. The use of pharmacologic and/or dietary interventions to treat dyslipoproteinemias has already shown that these therapeutic modalities may affect selectively individual apolipoprotein-defined lipoproteins, and thus allow the selection of individualized treatments targeted at decreasing harmful and/or increasing beneficial lipoprotein subclasses.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Gofman JW, De Lalla O, Glazier F, et al.: The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis, and coronary heart disease. Plasma 1954, 2:413–484.
Jones HB, Gofman JW, Lindgren FT, et al.: Lipoproteins in atherosclerosis. Am J Med 1951, 11:358–380.
Nichols AV: Human serum lipoproteins and their interrelationships. Adv Biol Med Phys 1967, 11:109–158.
Fredrickson DS, Levy RI, Lees RS: Fat transport in lipoproteins: an integrated approach to mechanism and disorders. N Engl J Med 1967, 276:32–281.
Ewing AM, Freeman NK, Lindgren FT: The analysis of human serum lipoprotein distributions. Adv Lipid Res 1965, 3:25–61.
Nestel P, Billington T, Tada N, et al.: Heterogeneity of very-low-density lipoprotein metabolism in hyperlipidemic subjects. Metabolism 1983, 32:810–817.
Nestel P: High-density lipoprotein turnover. Am Heart J 1987, 113:518–521.
Packard CJ, Shepherd J: Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997, 17:3542–3556.
Alaupovic P: Conceptual development of the classification systems of plasma lipoproteins. Protides Biol Fluids Proc Colloq 1972, 19:9–19.
Osborne JC Jr, Brewer HB Jr: The plasma lipoproteins. Adv Protein Chem 1977, 31:253–337.
Alaupovic P: Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families. Prog Lipid Res 1991, 30:105–138.
Fredrickson DS: Phenotyping. On reaching base camp (1950–1975). Circulation 1993, 87(suppl II):1–15.
Alaupovic P, Lee DM, McConathy WJ: Studies on the composition and structure of plasma lipoproteins. Distribution of lipoprotein families in major density classes of normal human plasma lipoproteins. Biochim Biophys Acta 1972, 260:689–707.
Lee DM, Alaupovic P: Composition and concentration of apolipoproteins in very-low- and low-density lipoproteins of normal human plasma. Atherosclerosis 1974, 19:501–520.
Lee DM, Alaupovic P: Apolipoproteins B, C-III and E in two major subpopulations of low-density lipoproteins. Biochim Biophys Acta 1986, 879:126–133.
Cheung MC, Albers JJ: Distribution of cholesterol and apolipoprotein A-I and A-II in human high density lipoprotein subtractions separated by NaCl equilibrium gradient centrifugation: evidence for HDL subpopulations with differing A-I/A-II molar ratios. J Lipid Res 1979, 20:200–207.
Alaupovic P: Significance of apolipoproteins for structure, function and classification of plasma lipoproteins. In Methods in Enzymology. Plasma Lipoproteins, Part C, Quantitation. Edited by Bradley WA, Gianturco SH, Segrest JP. San Diego: Academic Press; 1996.
Bekaert ED, Alaupovic P, Knight-Gibson C, et al.: Composition of plasma ApoA-I-containing lipoprotein particles in children and adults. Pediatr Res 1991, 29:315–321.
Ohta T, Ikeda Y, Nakamura R, et al.: Lipoprotein-containing apolipoprotein A-I-sex-related quantitative and qualitative changes in this lipoprotein subspecies after ingestion of fat. Am J Clin Nutr 1992, 56:404–409.
Rader DJ, Castro G, Zech LA, et al.: In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I:A-II. J Lipid Res 1991, 32:1849–1859.
Hannuksela ML, Brousseau ME, Meyn SM, et al.: In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II. Atherosclerosis 2002, 165:205–220.
Fielding CJ, Fielding PE: Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc Natl Acad Sci USA 1981, 78:3911–3914.
Barkia A, Puchois P, Ghalim N, et al.: Differential role of apolipoprotein A1-containing particles in cholesterol efflux from adipose cells. Atherosclerosis 1991, 87:135–146.
Cheung MC, Wolf AC, Lum KD, et al.: Distribution and localization of lecithin:cholesterol acyltransferase and cholesteryl ester transfer activity in A-I-containing lipoproteins. J Lipid Res 1986, 27:1135–1144.
Rinninger F, Kaiser T, Windler E, et al.: Selective uptake of cholesteryl esters from high-density lipoprotein-derived LpA-I and LpA-I:A-II particles by hepatic cells in culture. Biochim Biophys Acta 1998, 1393:277–291.
Alaupovic P: David Rubenstein Memorial Lecture: the biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can J Biochem 1981, 59:565–579.
James RW, Pometta D: Postprandial lipemia differentially influences high density lipoprotein subpopulations LpAI and LpAI,AII. J Lipid Res 1994, 35:1583–1591.
Dashti N, Alaupovic P, Knight-Gibson C, et al.: Identification and partial characterization of discrete apolipoprotein B-containing lipoprotein particles produced by human hepatoma cell line HepG2. Biochemistry 1987, 26:4837–4846.
Alaupovic P, Knight-Gibson C, Wang CS, et al.: Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. J Lipid Res 1991, 32:9–19.
Koren E, Alaupovic P, Lee DM, et al.: Selective isolation of human plasma low-density lipoprotein particles containing apolipoproteins B and E by use of a monoclonal antibody to apolipoprotein B. Biochemistry 1987, 26:2734–2740.
Agnani G, Bard JM, Candelier L, et al.: Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. Arterioscler Thromb 1991, 11:1021–1029.
Clavey V, Lestavel-Delattre S, Copin C, et al.: Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995, 15:963–971.
Koren E, Koscec M, Corder C, et al.: Differential atherogenicity of complex apoB-containing lipoprotein particles. Atherosclerosis 1994, 109:217–218.
Wallace RB, Anderson RA: Blood lipids, lipid-related measures and the risk of atherosclerotic cardiovascular disease. Epidemiol Rev 1987, 9:95–119.
März W, Trommlitz M, Gross W: Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I. J Clin Chem Clin Biochem 1988, 26:573–578.
Alaupovic P, Tavella M, Fesmire J: Separation and identification of apoB-containing lipoprotein particles in normolipidemic subjects and patients with hyperlipoproteinemias. Adv Exp Med Biol 1987, 210:7–14.
Alaupovic P, Koren E: Immunoaffinity chromatography of plasma lipoprotein particles. In Analyses of Fats, Oils and Lipoproteins. Edited by Perkins EG. Champaign, IL: American Oil Chemists’ Society; 1991.
Koren E, Puchois P, Alaupovic P, et al.: Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. Clin Chem 1987, 33:38–43.
Parra HJ, Mezdour H, Ghalim N, et al.: Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem 1990, 36:1431–1435.
Alaupovic P, Fesmire JD, Hunninghake D, et al.: The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. Atherosclerosis 1999, 146:369–379.
Puchois P, Kandoussi A, Fievet P, et al.: Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987, 68:35–40.
Coste-Burel M, Mainard F, Chivot L, et al.: Study of lipoprotein particles LpAI and LpAI:AII in patients before coronary bypass surgery. Clin Chem 1990, 36:1889–1891.
Montali A, Vega GL, Grundy SM: Concentrations of apolipoprotein A-I-containing particles in patients with hypoalphalipoproteinemia. Arterioscler Thromb 1994, 14:511–517.
Cheung MC, Brown BG, Wolf AC, et al.: Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991, 32:383–394.
O’Brien T, Nguyen TT, Hallaway BJ, et al.: The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol 1995, 15:228–231.
Duverger N, Rader D, Brewer HB Jr: Distribution of subclasses of HDL containing ApoA-I without ApoA-II (LpA-I) in normolipidemic men and women. Arterioscler Thromb 1994, 14:1594–1599.
Alaupovic P, Mack WJ, Knight-Gibson C, et al.: The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997, 17:715–722.
Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.
Asztalos BF, Batista M, Horvath KV, et al.: Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:847–852.
Luc G, Bard JM, Ferrières J, et al.: Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease—The PRIME Study. Arterioscler Thromb Vasc Biol 2002, 22:1155–1161.
Nordestgaard BG, Tybaerg-Hansen A: IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol 1992, 8:92–98.
Gould AL, Rossouw JE, Santanello NC, et al.: Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998, 97:946–952.
Alaupovic P: On the atherogenicity of triglyceride-rich lipoproteins and a novel marker for the assessment of their atherogenic potentials. OCL 2002, 9:220–226.
Hokanson JE, Austin MA: Plasma triglyceride levels is an independent risk factor for cardiovascular disease: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213–219.
Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000, 86:943–949.
Ginsberg HN: New perspectives in atherogenesis. Role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002, 106:2137–2142.
Zilversmit DB: Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem 1995, 41:153–158.
Blankenhorn DH, Alaupovic P, Wickham E, et al.: Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts—lipid and nonlipid factors. Circulation 1990, 81:470–476.
Alaupovic P, Blankenhorn DH: Identification of potentially atherogenic lipoprotein particles. In Molecular Biology of Atherosclerosis, Proceedings of the 57th European Atherosclerosis Meeting. Edited by Halpern MJ. London: John Libbey & Company; 1992.
Sacks FM, Alaupovic P, Moye LA, et al.: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) Trial. Circulation 2000, 102:1886–1892.
Koren E, Corder C, Mueller G, et al.: Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis 1996, 122:105–115.
Alaupovic P, Bard JM, Tavella M, et al.: Identification of apoB-containing lipoprotein families in NIDDM. Diabetes 1992, 41(suppl 2):18–25.
Gervaise N, Garrigue MA, Lasfargues G, et al.: Triglycerides, apoC3 and LpB:C3 and cardiovascular risk in type II diabetes. Diabetologia 2000, 43:703–708.
Lee SJ, Campos H, Moye LA, et al.: LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003, 23:853–858.
Atmeh RG, Shepherd J, Packard CJ: Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic profiles and response to drug therapy. Biochim Biophys Acta 1983, 751:175–188.
Bard JM, Parra HJ, Camare R, et al.: A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992, 41:498–503.
Bard JM, Parra HJ, Douste-Blazy P, et al.: Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism 1990, 39:269–273.
Schweitzer M, Tessier D, Vlahos WD, et al.: A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 2002, 162:201–210.
Alaupovic P, Heinonen T, Shurzinske L, et al.: Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis 1997, 133:123–133.
Alaupovic P, Knight-Gibson C, Plotkin D, et al.: Effect of simvastatin on apoB-containing lipoproteins in patients with hypertriglyceridemia. Abstract Book, XIV International Symposium on Drugs Affecting Lipid Metabolism. New York: NY. 2001.
Delplanque B, Richard JL, Jacotot B: Influence of diet on the plasma levels and distribution of apoA-I-containing lipoprotein particles. Prog Lipid Res 1991, 30:159–170.
Fumeron F, Brigant L, Parra HJ, et al.: Lowering of HDL2-cholesterol and lipoprotein A-I particle levels by increasing the ratio of polyunsaturated to saturated fatty acids. Am J Clin Nutr 1991, 53:655–659.
Cheung MC, Lichtenstein AH, Schaefer EJ: Effects of a diet restricted in saturated fatty acids and cholesterol on the composition of apolipoprotein A-I-containing lipoprotein particles in the fasting and fed states. Am J Clin Nutr 1994, 60:911–918.
Montoya MT, Porres A, Serrano S, et al.: Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations, and cholesterol efflux capacity. Am J Clin Nutr 2002, 75:484–491.
Lee DM, Alaupovic P, Gibson C, et al.: Effect of postprandial state on lipids, apolipoproteins and lipoprotein particles in normal and hypertriglyceridemic subjects. Atherosclerosis 1994, 109:217.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alaupovic, P. The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Curr Atheroscler Rep 5, 459–467 (2003). https://doi.org/10.1007/s11883-003-0036-8
Issue Date:
DOI: https://doi.org/10.1007/s11883-003-0036-8